<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="cffa5af8-7472-4775-a6f7-5bdf1e4fecaa"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use JEMPERLI safely and effectively. See full prescribing information for JEMPERLI.<br/>
      <br/>JEMPERLI (dostarlimab-gxly) injection, for intravenous use<br/>Initial U.S. Approval: 2021</title>
   <effectiveTime value="20240801"/>
   <setId root="095eab9f-545a-4f12-bfb7-19477fb901a5"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="167380711" root="1.3.6.1.4.1.519.1"/>
            <name>GlaxoSmithKline LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="53ef695b-2234-45ef-8524-52d523cec09f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20210422"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0173-0898" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Jemperli</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dostarlimab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="P0GVQ9A4S5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOSTARLIMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="P0GVQ9A4S5" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOSTARLIMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F7LTH1E20Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE HYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0173-0898-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761174" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <effectiveTime>
                              <low value="20210422"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_fbd9e2c8-7cef-493e-bdf5-db5daceb0a59">
               <id root="3ae51c09-7307-48b8-aca9-99f1bf4501ef"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="85%"/>
                           <col width="15%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Indications and Usage (<linkHtml href="#ID_fb5a4501-49ab-4ad5-abfb-2dd6dba89fed">1.1</linkHtml>)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8/2024</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Dosage and Administration (<linkHtml href="#ID_f7a65271-eeee-40a7-af25-0a2bb1d25844">2.1</linkHtml>, <linkHtml href="#ID_a4768fb4-7df5-4e83-87c4-ddb73a4d1a78">2.2</linkHtml>)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8/2024</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Warnings and Precautions, Severe and Fatal Immune-Mediated Adverse Reactions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3/2024</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_a9abdf52-e53a-4d88-b587-711ce6862af8">
               <id root="cb44dc0c-7921-483d-87af-24d436d28466"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1	INDICATIONS AND USAGE </title>
               <effectiveTime value="20240801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated:</paragraph>
                        <paragraph>
                           <content styleCode="underline">Endometrial Cancer </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). (<linkHtml href="#ID_fb5a4501-49ab-4ad5-abfb-2dd6dba89fed">1.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. (<linkHtml href="#ID_fb5a4501-49ab-4ad5-abfb-2dd6dba89fed">1.1</linkHtml>, <linkHtml href="#ID_f7a65271-eeee-40a7-af25-0a2bb1d25844">2.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Mismatch Repair Deficient Recurrent or Advanced Solid Tumors</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.<sup>1</sup> (<linkHtml href="#ID_58af00a3-f790-49a4-8df8-05ea43b8136a">1.2</linkHtml>, <linkHtml href="#ID_f7a65271-eeee-40a7-af25-0a2bb1d25844">2.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <sup>1</sup>This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (<linkHtml href="#ID_58af00a3-f790-49a4-8df8-05ea43b8136a">1.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_fb5a4501-49ab-4ad5-abfb-2dd6dba89fed">
                     <id root="3549f7e1-fa7e-4b9b-81df-b085fa4d7d8a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Endometrial Cancer</title>
                     <text>
                        <paragraph>JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).</paragraph>
                        <paragraph>JEMPERLI, as a single agent, is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_f7a65271-eeee-40a7-af25-0a2bb1d25844">2.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_58af00a3-f790-49a4-8df8-05ea43b8136a">
                     <id root="ab6b725f-912f-46d2-bdf2-b6de998c010a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Mismatch Repair Deficient Recurrent or Advanced Solid Tumors</title>
                     <text>
                        <paragraph>JEMPERLI, as a single agent, is indicated for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_f7a65271-eeee-40a7-af25-0a2bb1d25844">2.1</linkHtml>)].</content> This indication is approved under accelerated approval based on tumor response rate and durability of response <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_0a31d7a2-1ce0-485e-b192-8b3dda7b9f77">14.2</linkHtml>)].</content> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b1e7e5c6-489e-4f20-8565-f663b16fd96e">
               <id root="44a609d3-15a0-4bfd-a76a-952057bd56d1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2	DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20240801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>JEMPERLI, in combination with carboplatin and paclitaxel, for primary advanced or recurrent EC: 500 mg every 3 weeks for 6 cycles followed by 1,000 mg monotherapy every 6 weeks for all cycles thereafter. (<linkHtml href="#ID_a4768fb4-7df5-4e83-87c4-ddb73a4d1a78">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>JEMPERLI, as a single agent, for dMMR recurrent or advanced EC: 500 mg every 3 weeks for 4 cycles followed by 1,000 mg every 6 weeks for all cycles thereafter. (<linkHtml href="#ID_a4768fb4-7df5-4e83-87c4-ddb73a4d1a78">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>JEMPERLI, as a single agent, for dMMR recurrent or advanced solid tumors: 500 mg every 3 weeks for 4 cycles followed by 1,000 mg every 6 weeks for all cycles thereafter. (<linkHtml href="#ID_a4768fb4-7df5-4e83-87c4-ddb73a4d1a78">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Administer as an intravenous infusion over 30 minutes. (<linkHtml href="#ID_a4768fb4-7df5-4e83-87c4-ddb73a4d1a78">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>For complete dosing instructions, see full prescribing information.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f7a65271-eeee-40a7-af25-0a2bb1d25844">
                     <id root="186c1895-99a3-4067-a2b6-efc87fd1513a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Patient Selection</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Single Agent</content>
                        </paragraph>
                        <paragraph>Select patients for treatment with JEMPERLI as a single agent based on the presence of dMMR in tumor specimens in:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>recurrent or advanced EC<content styleCode="italics"> [see Clinical Studies (<linkHtml href="#ID_cca2cd2a-8ab4-4352-a019-13d0b81835ed">14.1</linkHtml>)]</content>. </item>
                           <item>
                              <caption>•</caption>recurrent or advanced solid tumors <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_0a31d7a2-1ce0-485e-b192-8b3dda7b9f77">14.2</linkHtml>)]</content>.</item>
                        </list>
                        <paragraph>Information on FDA-approved tests for the detection of dMMR status is available at <linkHtml href="https://www.fda.gov/companiondiagnostics">https://www.fda.gov/companiondiagnostics</linkHtml>. </paragraph>
                        <paragraph>Because the effect of prior chemotherapy on test results for dMMR in patients with high-grade gliomas is unclear, it is recommended to test for this marker in the primary tumor specimen obtained prior to initiation of temozolomide chemotherapy in patients with high-grade gliomas.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a4768fb4-7df5-4e83-87c4-ddb73a4d1a78">
                     <id root="edd9f2e1-4342-4690-9084-279b554d3a13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage </title>
                     <text>
                        <paragraph>The recommended dosage for JEMPERLI is presented in <linkHtml href="#_RefTable_1">Table 1</linkHtml>.</paragraph>
                        <table ID="_RefTable_1" width="100%">
                           <caption>Table 1. Recommended Dosage of JEMPERLI</caption>
                           <col width="38%"/>
                           <col width="38%"/>
                           <col width="24%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">dMMR = Mismatch Repair Deficient; EC = endometrial cancer.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup> 30-minute intravenous infusion.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>b</sup> Refer to the Prescribing Information for the agents administered in combination with JEMPERLI, as appropriate.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Indication</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Recommended Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Duration/Timing of Treatment</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Combination Therapy</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Adults with primary advanced or recurrent EC</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg<sup>a</sup> JEMPERLI every 3 weeks for 6  cycles in combination with carboplatin and paclitaxel<sup>b</sup> followed by</paragraph>
                                    <paragraph>1,000 mg JEMPERLI as monotherapy every 6 weeks for all cycles thereafter.</paragraph>
                                    <paragraph>Administer JEMPERLI prior to carboplatin and paclitaxel when given on the same day.</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Until disease progression, unacceptable toxicity, or up to 3 years.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Monotherapy</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Adults with dMMR recurrent or advanced EC and</paragraph>
                                    <paragraph>dMMR recurrent or advanced solid tumors</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>500 mg<sup>a</sup> JEMPERLI every 3 weeks for 4 cycles followed by</paragraph>
                                    <paragraph>1,000 mg<sup>a</sup> JEMPERLI every 6 weeks for all cycles thereafter.</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Until disease progression or unacceptable toxicity.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">
                     <id root="1cc56038-0151-4f01-8acd-ef3aff594feb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>No dose reductions of JEMPERLI are recommended. In general, withhold JEMPERLI for severe (Grade 3) immune‑mediated adverse reactions. Permanently discontinue JEMPERLI for life‑threatening (Grade 4) immune‑mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone equivalent per day within 12 weeks of initiating steroids.</paragraph>
                        <paragraph>Dosage modifications for JEMPERLI for adverse reactions that require management different from these general guidelines are summarized in <linkHtml href="#_RefTable_2">Table 2</linkHtml>.</paragraph>
                        <table ID="_RefTable_2" width="100%">
                           <caption>Table 2. Recommended Dosage Modifications for Adverse Reactions</caption>
                           <col width="32%"/>
                           <col width="34%"/>
                           <col width="34%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">ALT = alanine aminotransferase; AST = aspartate aminotransferase; DRESS = drug rash with eosinophilia and systemic symptoms; SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; ULN = upper limit of normal.<br/>
                                    <sup>a</sup> Based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0.<br/>
                                    <sup>b</sup> Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no <br/>  complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or<br/>  equivalent) within 12 weeks of initiating steroids.<br/>
                                    <sup>c</sup> If AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently <br/>  discontinue JEMPERLI based on recommendations for hepatitis with no liver involvement.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Severity<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dosage Modification</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Immune-Mediated Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pneumonitis</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 3 or 4 or recurrent Grade 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Colitis</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 2 or 3</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hepatitis with no tumor involvement of the liver</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>AST or ALT increases to more than 3 and up to 8 times ULN</paragraph>
                                    <paragraph>or </paragraph>
                                    <paragraph>Total bilirubin increases to more than 1.5 and up to 3 times ULN</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>AST or ALT increases to more than 8 times ULN</paragraph>
                                    <paragraph>or </paragraph>
                                    <paragraph>Total bilirubin increases to more than 3 times ULN</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hepatitis with tumor involvement of the liver<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN</paragraph>
                                    <paragraph>or</paragraph>
                                    <paragraph>Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>AST or ALT increases to more than 10 times ULN</paragraph>
                                    <paragraph>or </paragraph>
                                    <paragraph>Total bilirubin increases to more than 3 times ULN</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Endocrinopathies</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 2, 3, or 4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold until clinically stable or permanently discontinue, depending on severity<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nephritis with renal dysfunction</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 2 or 3 increased blood creatinine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 4 increased blood creatinine </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Exfoliative dermatologic conditions</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Suspected SJS, TEN, or DRESS</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Confirmed SJS, TEN, or DRESS</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Myocarditis</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 2, 3, or 4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Neurological toxicities</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Withhold<sup>b</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 3 or 4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Other Adverse Reactions</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Infusion-related reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_b6dd660a-5c83-4779-80cb-1008df33d0ab">5.2</linkHtml>)]</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Grade 1 or 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Interrupt or slow the rate of infusion</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Grade 3 or 4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Permanently discontinue</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f6add666-a215-47ba-b566-14e237b40f56">
                     <id root="e72ed7ba-bd28-441e-9679-c6acb63d883f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Preparation and Administration </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Preparation for Intravenous Infusion</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Visually inspect the solution for particulate matter and discoloration. The solution is clear to slightly opalescent, colorless to yellow. Discard the vial if visible particles are observed.</item>
                           <item>
                              <caption>•</caption>Do not shake.</item>
                           <item>
                              <caption>•</caption>JEMPERLI is compatible with an infusion bag made of polyolefin, ethylene vinyl acetate, or polyvinyl chloride with di(2-ethylhexyl) phthalate (DEHP).</item>
                           <item>
                              <caption>•</caption>For the 500-mg dose, withdraw 10 mL of JEMPERLI from a vial using a disposable sterile syringe made of polypropylene and dilute into an intravenous infusion bag containing 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to a final concentration between 2 to 10 mg/mL (maximum 250 mL).</item>
                           <item>
                              <caption>•</caption>For the 1,000-mg dose, withdraw 10 mL from each of 2 vials (withdraw 20 mL total) and dilute into an intravenous bag containing 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to a final concentration between 4 to 10 mg/mL (maximum 250 mL).</item>
                           <item>
                              <caption>•</caption>Mix diluted solution by gentle inversion. Do not shake.</item>
                           <item>
                              <caption>•</caption>Discard any unused portion left in the vial.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Storage of Infusion Solution</content>
                        </paragraph>
                        <paragraph>Store in the original carton until time of preparation in order to protect from light. The prepared dose may be stored either:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>At room temperature for no more than 6 hours from the time of preparation until the end of infusion.</item>
                           <item>
                              <caption>•</caption>Under refrigeration at 2°C to 8°C (36ºF to 46ºF) for no more than 24 hours from time of preparation until end of infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration.</item>
                        </list>
                        <paragraph>Discard after 6 hours at room temperature or after 24 hours under refrigeration.</paragraph>
                        <paragraph>Do not freeze.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <paragraph>Administer infusion solution intravenously over 30 minutes through an intravenous line using tubing made of polyvinyl chloride or platinum cured silicon; fittings made of polyvinyl chloride or polycarbonate; and a sterile, non-pyrogenic, low‑protein binding, 0.2-micron, in-line or add-on filter.</paragraph>
                        <paragraph>JEMPERLI must not be administered as an intravenous push or bolus injection. Do not co‑administer other drugs through the same infusion line.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c9c5184e-8ee7-463d-ad3f-c9d28114782a">
               <id root="c1399712-fce3-43ad-8f94-0169dca5e49e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3	DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Injection: 500 mg/10 mL (50 mg/mL) clear to slightly opalescent, colorless to yellow solution in a single-dose vial for intravenous infusion after dilution.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 500 mg/10 mL (50 mg/mL) solution in a single-dose vial. (<linkHtml href="#ID_c9c5184e-8ee7-463d-ad3f-c9d28114782a">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_ab71ee9b-af2b-4c1a-b4e3-9be69b2de3a4">
               <id root="d0441d62-1dc0-438c-9e7d-640bf4cc5a8c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4	CONTRAINDICATIONS </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20200522"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#ID_ab71ee9b-af2b-4c1a-b4e3-9be69b2de3a4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_97cc15bc-5179-4023-b644-e37c3aca2029">
               <id root="0044f844-9d7d-4d4f-9713-82ae48c55450"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5	WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20240801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune‑mediated pneumonitis, immune-mediated colitis, immune‑mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune‑mediated dermatologic adverse reactions, and solid organ transplant rejection. Monitor for signs and symptoms of immune‑mediated adverse reactions. Evaluate clinical chemistries, including liver enzymes, creatinine, and thyroid function, at baseline and periodically during treatment. Withhold or permanently discontinue JEMPERLI and administer corticosteroids based on the severity of reaction. (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>, <linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Infusion-related reactions: Interrupt, slow the rate of infusion, or permanently discontinue JEMPERLI based on severity of reaction. (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>, <linkHtml href="#ID_b6dd660a-5c83-4779-80cb-1008df33d0ab">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Complications of allogeneic hematopoietic stem cell transplantation (HSCT): Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD‑1/PD-L1–blocking antibody. (<linkHtml href="#ID_77ae6955-4971-43bc-a718-a357905f28c5">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#ID_982b8f4b-e023-43b1-ba00-d7a7ef9c5079">5.4</linkHtml>, <linkHtml href="#ID_fdc49f15-59dc-428e-9791-85f45526697c">8.1</linkHtml>, <linkHtml href="#ID_133b43da-b996-4e08-8694-7d62293d02b1">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_4984c2ce-7d02-4519-ad57-91e478a379a5">
                     <id root="7e7878f8-9858-4ef5-91f6-02306f9856be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Severe and Fatal Immune-Mediated Adverse Reactions </title>
                     <text>
                        <paragraph>JEMPERLI is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance, and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed in WARNINGS AND PRECAUTIONS may not include all possible severe and fatal immune‑mediated reactions.</paragraph>
                        <paragraph>Immune-mediated adverse reactions, which can be severe or fatal, can occur in any organ system or tissue. Immune‑mediated adverse reactions can occur at any time after starting a PD-1/PD-L1–blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1–blocking antibodies, they can also manifest after discontinuation of PD-1/PD-L1–blocking antibodies.</paragraph>
                        <paragraph>Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD‑1/PD‑L1–blocking antibodies. Monitor closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function tests at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</paragraph>
                        <paragraph>Withhold or permanently discontinue JEMPERLI depending on severity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>)]</content>. In general, if JEMPERLI requires interruption or discontinuation, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reaction is not controlled with corticosteroids.</paragraph>
                        <paragraph>Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies, dermatologic reactions) are discussed below.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune-Mediated Pneumonitis</content>
                        </paragraph>
                        <paragraph>JEMPERLI can cause immune-mediated pneumonitis, which can be fatal. In patients treated with other PD-1/PD-L1–blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation.</paragraph>
                        <paragraph>Immune-mediated pneumonitis occurred in 2.3% (14/605) of patients receiving JEMPERLI, including Grade 2 (1.3%), Grade 3 (0.8%) and Grade 4 (0.2%) pneumonitis. Pneumonitis led to discontinuation of JEMPERLI in 1.3% of patients.</paragraph>
                        <paragraph>Systemic corticosteroids were required in 79% (11/14) of patients with pneumonitis. Pneumonitis resolved in 11 of the 14 patients. JEMPERLI was withheld for 9 patients. Five patients reinitiated JEMPERLI after symptom improvement; of these, 2 patients had recurrence of pneumonitis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune-Mediated Colitis</content>
                        </paragraph>
                        <paragraph>JEMPERLI can cause immune-mediated colitis. Cytomegalovirus infection/reactivation have occurred in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1–blocking antibodies. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.</paragraph>
                        <paragraph>Immune-mediated colitis occurred in 1.3% (8/605) of patients receiving JEMPERLI, including Grade 2 (0.7%) and Grade 3 (0.7%) adverse reactions. Colitis led to discontinuation of JEMPERLI in 1 (0.2%) patient.</paragraph>
                        <paragraph>Systemic corticosteroids were required in 75% (6/8) of patients with colitis. Colitis resolved in 5 of the 8 patients. Of the 4 patients in whom JEMPERLI was withheld for colitis, all reinitiated treatment with JEMPERLI; of these, 1 patient had recurrence of colitis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune-Mediated Hepatitis</content>
                        </paragraph>
                        <paragraph>JEMPERLI can cause immune-mediated hepatitis, which can be fatal.</paragraph>
                        <paragraph>Immune-mediated hepatitis occurred in 0.5% (3/605) of patients receiving JEMPERLI, all were Grade 3. Hepatitis led to discontinuation of JEMPERLI in 1 (0.2%) patient. Systemic corticosteroids were required in 2 patients with hepatitis and the events resolved in 2 of the 3 patients.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune-Mediated Endocrinopathies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adrenal Insufficiency:</content> JEMPERLI can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Adrenal insufficiency occurred in 1.2% (7/605) patients receiving JEMPERLI, including Grade 2 (0.5%) and Grade 3 (0.7%). Adrenal insufficiency resulted in discontinuation in 1 (0.2%) patient and resolved in 4 of the 7 patients. Of the 4 patients in whom JEMPERLI was withheld for adrenal insufficiency, all reinitiated treatment with JEMPERLI. Systemic corticosteroids were required in 5 of the 7 patients with adrenal insufficiency.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypophysitis:</content> JEMPERLI can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>          <content styleCode="italics">JEMPERLI in Combination with Carboplatin and Paclitaxel:</content> Hypophysitis (Grade 3) occurred in 0.4% (1/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel. Systemic corticosteroids were required, and the event resolved. JEMPERLI was withheld and the patient reinitiated treatment.</paragraph>
                        <paragraph>          <content styleCode="italics">JEMPERLI as a Single Agent:</content> Hypophysitis (Grade 2) occurred in 0.2% (1/605) of patients receiving JEMPERLI as a single agent. Systemic corticosteroids were required, and the event did not resolve. JEMPERLI was withheld and the patient reinitiated treatment.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Thyroid Disorders:</content> JEMPERLI can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate thyroid hormone replacement or medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Thyroiditis:</content> Thyroiditis occurred in 0.5% (3/605) of patients receiving JEMPERLI; all were Grade 2. Systemic corticosteroids were required in 1 of 3 patients and anti-thyroid therapy was required for 2 of 3 patients with thyroiditis. JEMPERLI was withheld for 1 patient and the patient reinitiated treatment. None of the events of thyroiditis resolved; there were no discontinuations of JEMPERLI due to thyroiditis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypothyroidism: JEMPERLI in Combination with Carboplatin and Paclitaxel:</content> Hypothyroidism occurred in 12% (30/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel, all of which were Grade 2. Hypothyroidism led to discontinuation of JEMPERLI in 1 patient and resolved in 23% (7/30) of patients. JEMPERLI was withheld for 5 patients and all reinitiated treatment with JEMPERLI. Thyroid hormone replacement was required for 27 of the 30 patients with hypothyroidism.</paragraph>
                        <paragraph>          <content styleCode="italics">JEMPERLI as a Single Agent:</content> Hypothyroidism occurred in 8% (46/605) of patients receiving JEMPERLI as a single agent, all of which were Grade 2. Hypothyroidism did not lead to discontinuation of JEMPERLI and resolved in 37% (17/46) of patients. JEMPERLI was withheld for 2 patients and both reinitiated treatment. Thyroid hormone replacement therapy was required for 45 of the 46 patients with hypothyroidism.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hyperthyroidism: JEMPERLI in Combination with Carboplatin and Paclitaxel:</content> Hyperthyroidism occurred in 3.3% (8/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel, including Grade 2 (2.9%) and Grade 3 (0.4%). Hyperthyroidism did not lead to discontinuation of JEMPERLI and resolved in 75% (6/8) of patients<content styleCode="italics">.</content> JEMPERLI was withheld for 1 patient and the patient reinitiated treatment. Anti-thyroid therapy was required for 2 of the 8 patients while systemic corticosteroids were required for 1 of the 8 patients with hyperthyroidism.</paragraph>
                        <paragraph>          <content styleCode="italics">JEMPERLI as a Single Agent:</content> Hyperthyroidism occurred in 2.3% (14/605) of patients receiving JEMPERLI as a single agent, including Grade 2 (2.1%) and Grade 3 (0.2%). Hyperthyroidism did not lead to discontinuation of JEMPERLI and resolved in 71% (10/14) of the 14 patients. JEMPERLI was withheld for 2 patients and both reinitiated treatment. Anti-thyroid therapy was required for 10 of the 14 patients with hyperthyroidism.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis:</content> JEMPERLI can cause type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>          <content styleCode="italics">JEMPERLI in Combination with Carboplatin and Paclitaxel:</content> Type 1 diabetes mellitus (Grade 3) occurred in 0.4% (1/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel. Type 1 diabetes mellitus led to withholding JEMPERLI; the patient reinitiated treatment and required long-term insulin therapy.</paragraph>
                        <paragraph>          <content styleCode="italics">JEMPERLI as a Single Agent:</content> Type 1 diabetes mellitus occurred in 0.2% (1/605) of patients receiving JEMPERLI as a single agent, which was Grade 3. Type 1 diabetes mellitus did not result in treatment discontinuation and did not resolve.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune-Mediated Nephritis with Renal Dysfunction</content>
                        </paragraph>
                        <paragraph>JEMPERLI can cause immune-mediated nephritis, which can be fatal. Nephritis, including tubulointerstitial nephritis, occurred in 0.5% (3/605) of patients receiving JEMPERLI; all were Grade 2. Nephritis led to discontinuation of JEMPERLI in 1 (0.2%) patient and resolved in all patients. JEMPERLI was withheld for 1 patient and the patient reinitiated treatment. Systemic corticosteroids were required in 2 of the 3 patients experiencing nephritis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune-Mediated Dermatologic Adverse Reactions</content>
                        </paragraph>
                        <paragraph>JEMPERLI can cause immune-mediated rash or dermatitis. Bullous and exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), have occurred with PD‑1/PD‑L1–blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes. Withhold or permanently discontinue JEMPERLI depending on severity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Immune-Mediated Adverse Reactions</content>
                        </paragraph>
                        <paragraph>The following clinically significant immune-mediated adverse reactions occurred in &lt;1% of the 605 patients treated with JEMPERLI or were reported with the use of other PD-1/PD-L1–blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System:</content> Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain‑Barré syndrome, nerve paresis, autoimmune neuropathy.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac/Vascular:</content> Myocarditis, pericarditis, vasculitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ocular:</content> Uveitis, iritis, other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune‑mediated adverse reactions, consider a Vogt‑Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> Pancreatitis, including increases in serum amylase and lipase levels, gastritis, duodenitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue:</content> Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatica.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine:</content> Hypoparathyroidism.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Other (Hematologic/Immune):</content> Autoimmune hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection, other transplant (including corneal graft) rejection.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b6dd660a-5c83-4779-80cb-1008df33d0ab">
                     <id root="feaeca92-5b03-4d62-850e-079b507228ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Infusion-Related Reactions </title>
                     <text>
                        <paragraph>Severe or life-threatening infusion-related reactions have been reported with PD-1/PD-L1–blocking antibodies. Severe infusion-related reactions (Grade 3) occurred in 0.2% (1/605) of patients receiving JEMPERLI. All patients recovered from the infusion-related reactions.</paragraph>
                        <paragraph>Monitor patients for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion or permanently discontinue JEMPERLI based on severity of reaction <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_45494d7e-b2cd-4469-b5f9-f3d4b284d8db">2.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_77ae6955-4971-43bc-a718-a357905f28c5">
                     <id root="0257d9b8-bc57-4e49-8a08-08662a772408"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Complications of Allogeneic HSCT</title>
                     <text>
                        <paragraph>Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1–blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT.</paragraph>
                        <paragraph>Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1–blocking antibody prior to or after an allogeneic HSCT.</paragraph>
                     </text>
                     <effectiveTime value="20210817"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_982b8f4b-e023-43b1-ba00-d7a7ef9c5079">
                     <id root="c1a8393d-611e-4b84-b761-5a278ca4694b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on its mechanism of action, JEMPERLI can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus, resulting in fetal death. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JEMPERLI and for 4 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_fdc49f15-59dc-428e-9791-85f45526697c">8.1</linkHtml>, <linkHtml href="#ID_133b43da-b996-4e08-8694-7d62293d02b1">8.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20200522"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_80239aee-c3a8-4c59-8e4f-6f8320f75809">
               <id root="7e3f597e-06f1-4c90-891b-747e90808f71"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6	ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Severe and fatal immune-mediated adverse reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Infusion-related reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_b6dd660a-5c83-4779-80cb-1008df33d0ab">5.2</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Most common adverse reactions (≥20%), including laboratory abnormalities, with JEMPERLI in combination with carboplatin and paclitaxel in patients with EC are decreased hemoglobin, increased creatinine, peripheral neuropathy, decreased white blood cell count, fatigue, nausea, alopecia, decreased platelets, increased glucose, decreased lymphocytes, decreased magnesium, decreased neutrophils, increased aspartate aminotransferase (AST), arthralgia, rash, constipation, diarrhea, increased alanine aminotransferase (ALT), decreased potassium, decreased albumin, decreased sodium, increased alkaline phosphatase, abdominal pain, dyspnea, decreased appetite, increased amylase, decreased phosphate, urinary tract infection, and vomiting. (<linkHtml href="#ID_8f52d2dc-85ee-4d5d-8d9c-6ced272013ae">6.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Most common adverse reactions (≥20%) with JEMPERLI as a single agent in patients with dMMR solid tumors are fatigue/asthenia, anemia, diarrhea, and nausea. Most common Grade 3 or 4 laboratory abnormalities (≥2%) are decreased lymphocytes, decreased sodium, increased alkaline phosphatase, and decreased albumin. (<linkHtml href="#ID_8f52d2dc-85ee-4d5d-8d9c-6ced272013ae">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or <linkHtml href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8f52d2dc-85ee-4d5d-8d9c-6ced272013ae">
                     <id root="3cdf472b-de67-4b0c-939f-0d37d09e24a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety population described in the <content styleCode="italics">Warnings and Precautions </content>for use of JEMPERLI in combination with carboplatin and paclitaxel was evaluated in 241 patients with primary advanced or recurrent EC in the randomized, double-blind, active-controlled RUBY trial.</paragraph>
                        <paragraph>Additionally, the pooled safety population described in <content styleCode="italics">Warnings and Precautions</content> reflects exposure to JEMPERLI as a single agent in 605 patients with advanced or recurrent solid tumors in the non-randomized, open-label, multicohort GARNET trial that enrolled 314 patients with EC and 291 patients with other solid tumors. JEMPERLI was administered intravenously at doses of 500 mg every 3 weeks for 4 cycles followed by 1,000 mg every 6 weeks until disease progression or unacceptable toxicity. Among the 605 patients, 32% were exposed for &gt;1 year and 19% were exposed for &gt;2 years.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Primary Advanced or Recurrent Endometrial Cancer: JEMPERLI in Combination with Carboplatin and Paclitaxel</content>
                        </paragraph>
                        <paragraph>The safety of JEMPERLI in patients with primary advanced or recurrent EC was evaluated in RUBY <content styleCode="italics">[see Clinical Studies (14.1)]</content>. Patients received JEMPERLI 500 mg (n = 241) or placebo (n = 246) in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles followed by JEMPERLI 1,000 mg or placebo every 6 weeks until disease progression or unacceptable toxicity. Among the 241 patients, 38.6% were exposed for &gt;1 year and 24.1% were exposed for &gt;2 years.</paragraph>
                        <paragraph>Serious adverse reactions occurred in 39% of patients receiving JEMPERLI in combination with carboplatin and paclitaxel; the most common serious adverse reactions were sepsis, including urosepsis (3.7%), and pulmonary embolism (3.3%). Fatal adverse reactions occurred in 1.2% of patients receiving JEMPERLI including septic shock (0.8%) and myelosuppression (0.4%).</paragraph>
                        <paragraph>In patients receiving JEMPERLI in combination with carboplatin and paclitaxel, JEMPERLI was permanently discontinued due to adverse reactions in 46 patients (19%). Adverse reactions that required permanent discontinuation in ≥2 patients included 3 cases (1.2%) of rash maculo-papular, and 2 cases (0.8%) each of increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), diarrhea, pancreatitis, fatigue, pneumonitis, and arthralgia.</paragraph>
                        <paragraph>Dosage interruptions due to an adverse reaction occurred in 37% of patients who received JEMPERLI in combination with carboplatin and paclitaxel. Adverse reactions that required dosage interruption in ≥5% of patients who received JEMPERLI in combination with carboplatin and paclitaxel were anemia, thrombocytopenia, and peripheral neuropathy.</paragraph>
                        <paragraph>The most common adverse reactions, including laboratory abnormalities (≥20%), were decreased hemoglobin, increased creatinine, peripheral neuropathy, decreased white blood cell count, fatigue, nausea, alopecia, decreased platelets, increased glucose, decreased lymphocytes, decreased magnesium, decreased neutrophils, increased AST, arthralgia, rash, constipation, diarrhea, increased ALT, decreased potassium, decreased albumin, decreased sodium, increased alkaline phosphatase, abdominal pain, dyspnea, decreased appetite, increased amylase, decreased phosphate, urinary tract infection, and vomiting.</paragraph>
                        <paragraph>
                           <linkHtml href="#_RefTable_3">Table 3</linkHtml> summarizes the adverse reactions that occurred in ≥20% of patients with primary advanced or recurrent EC receiving JEMPERLI in combination with carboplatin and paclitaxel in RUBY.</paragraph>
                        <table ID="_RefTable_3" width="100%">
                           <caption>Table 3. Adverse Reactions (≥20%) in Patients with Endometrial Cancer Who Received JEMPERLI with Carboplatin and Paclitaxel in RUBY</caption>
                           <col width="27%"/>
                           <col width="27%"/>
                           <col width="26%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">Graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Includes neuropathy peripheral and peripheral sensory neuropathy.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>b</sup> Includes fatigue and asthenia.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>c</sup> Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal discomfort, epigastric discomfort, and abdominal tenderness.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>d</sup> Includes rash, rash maculo-papular, palmar-plantar erythrodysesthesia syndrome, rash pustular, skin exfoliation, and vulvovaginal rash.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>e</sup> Includes dyspnea and dyspnea exertional.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>f</sup> Includes urinary tract infection, urinary tract infection bacterial, cystitis, and pyelonephritis.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI with Carboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 241</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Placebo withCarboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 246</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>Nervous System Disorders</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Peripheral neuropathy<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>64</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>61</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2.0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>General</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Fatigue<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>56</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>63</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>Gastrointestinal Disorders</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>54</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>46</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Constipation</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>35</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>36</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>32</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Abdominal pain<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>24</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Skin and Subcutaneous Tissue</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Alopecia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>54</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>50</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Rash<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>37</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>Musculoskeletal and Connective Tissue</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Arthralgia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>37</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>35</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Respiratory, Thoracic and Mediastinal Disorders</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Dyspnea<sup>e</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>23</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>26</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Metabolism and Nutrition Disorders</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Decreased appetite</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Infections and Infestations</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>     Urinary tract infection<sup>f</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>3.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt;20% of patients with primary advanced or recurrent EC who received JEMPERLI in combination with carboplatin and paclitaxel included:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine Disorders:</content> Hypothyroidism, hyperthyroidism, thyroiditis, adrenal insufficiency.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders:</content> Keratitis, uveitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> Colitis, pancreatitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutrition Disorders:</content> Type 1 diabetes mellitus.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> Immune-mediated arthritis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders:</content> Pneumonitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders:</content> Myocarditis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> Encephalopathy.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders:</content> Hypertension, hemorrhage.</paragraph>
                        <paragraph>
                           <linkHtml href="#_RefTable_4">Table 4</linkHtml> summarizes the laboratory abnormalities in patients with primary advanced or recurrent EC receiving JEMPERLI in combination with carboplatin and paclitaxel in RUBY.</paragraph>
                        <table ID="_RefTable_4" width="100%">
                           <caption>Table 4. Select Laboratory Abnormalities that Worsened from Baseline Occurring in ≥20% of Patients with Endometrial Cancer Receiving JEMPERLI with Carboplatin and Paclitaxel in RUBY</caption>
                           <col width="24%"/>
                           <col width="24%"/>
                           <col width="23%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">ALT = alanine aminotransferase; AST = aspartate aminotransferase.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Laboratory Test</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI with Carboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 241</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Placebo with Carboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 246</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>Hematology</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased hemoglobin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>83</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>16</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased white blood cell count</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>62</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>13</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>58</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>11</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased platelet count</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>48</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>4.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>48</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased lymphocytes</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>44</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>39</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased neutrophils</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>42</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>52</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>Chemistry</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased creatinine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>75</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>82</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased glucose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>47</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>44</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased AST</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>38</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>3.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>23</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased ALT</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>19</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased albumin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased alkaline phosphatase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>28</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased amylase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>Electrolytes</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased magnesium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>44</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>47</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased potassium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>4.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased sodium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>3.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>     Decreased phosphate</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>1.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>3.7</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Mismatch Repair Deficient Recurrent or Advanced Endometrial Cancer: JEMPERLI as a Single Agent </content>
                        </paragraph>
                        <paragraph>The safety of JEMPERLI was evaluated in GARNET in 150 patients with advanced or recurrent dMMR EC who received at least 1 dose of JEMPERLI <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_cca2cd2a-8ab4-4352-a019-13d0b81835ed">14.1</linkHtml>)]</content>. Patients received JEMPERLI 500 mg every 3 weeks for 4 cycles followed by 1,000 mg every 6 weeks as an intravenous infusion until disease progression or unacceptable toxicity. Patients with autoimmune disease that required systemic therapy within 2 years of treatment or a medical condition that required immunosuppression were ineligible. Among patients receiving JEMPERLI, 41% were exposed for &gt;1 year and 23% were exposed for &gt;2 years.</paragraph>
                        <paragraph>A fatal adverse reaction occurred in one patient (0.7%) who received JEMPERLI, due to concurrent immune-mediated encephalitis and urinary tract infection.</paragraph>
                        <paragraph>Serious adverse reactions occurred in 38% of patients receiving JEMPERLI. Serious adverse reactions in &gt;2% of patients included urinary tract infection (4%), sepsis (3.3%), acute kidney injury (2.7%), and abdominal pain (2.7%).</paragraph>
                        <paragraph>JEMPERLI was permanently discontinued due to adverse reactions in 15 (10%) patients, including increased transaminases, sepsis, bronchitis, pneumonitis, rash, pruritus, pancreatitis, encephalitis, and nephritis. Dosage interruptions due to an adverse reaction occurred in 28% of patients who received JEMPERLI. Adverse reactions that required dosage interruption in &gt;1% of patients who received JEMPERLI were anemia, diarrhea, asthenia, colitis, sepsis, and pneumonitis.</paragraph>
                        <paragraph>The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, nausea, diarrhea, constipation, vomiting, and rash.</paragraph>
                        <paragraph>
                           <linkHtml href="#_RefTable_5">Table 5</linkHtml> summarizes the adverse reactions that occurred in ≥10% of patients with dMMR EC on JEMPERLI in GARNET.</paragraph>
                        <table ID="_RefTable_5" width="100%">
                           <caption>Table 5. Adverse Reactions (≥10%) in Patients with dMMR Endometrial Cancer Who Received JEMPERLI in GARNET</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">dMMR = Mismatch Repair Deficient.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.<br/>
                                    <sup>a</sup> Includes fatigue and asthenia.<br/>
                                    <sup>b</sup> Includes anemia, decreased hemoglobin, iron deficiency, and iron deficiency anemia.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>c</sup> Includes rash, rash maculo-papular, rash pruritic, erythema, and pemphigoid.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>d </sup>Includes increased alanine aminotransferase, increased aspartate aminotransferase, increased transaminases, and <br/>  hypertransaminasemia.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 150</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>General and administration site</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Fatigue<sup>a</sup>
                                    </paragraph>
                                    <paragraph>     Pyrexia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>49</paragraph>
                                    <paragraph>13</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>3.3</paragraph>
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Blood and lymphatic system</paragraph>
                                    <paragraph>     Anemia<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>35</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>18</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Gastrointestinal</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>32</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>0.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>2.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Constipation</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>23</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>0.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>23</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Skin and subcutaneous tissue</paragraph>
                                    <paragraph>     Rash<sup>c</sup>
                                    </paragraph>
                                    <paragraph>     Pruritus</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>21</paragraph>
                                    <paragraph>19</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                    <paragraph>1.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Infections </paragraph>
                                    <paragraph>     Urinary tract infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>19</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Metabolism and nutrition</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Decreased appetite</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Respiratory, thoracic, and mediastinal</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Cough</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Musculoskeletal and connective tissue</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Myalgia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Investigations</paragraph>
                                    <paragraph>     Increased transaminases<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>13</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Endocrine Disorders</paragraph>
                                    <paragraph>     Hypothyroidism</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt;10% of patients who received JEMPERLI included:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine Disorders:</content> Hyperthyroidism, adrenal insufficiency, hypophysitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders:</content> Iridocyclitis, uveitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> Colitis, pancreatitis, enterocolitis, gastritis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions:</content> Chills.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> Immune-mediated myositis, immune-mediated arthritis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> Encephalitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders:</content> Nephritis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders:</content> Pneumonitis, interstitial lung disease.</paragraph>
                        <paragraph>
                           <linkHtml href="#_RefTable_6">Table 6</linkHtml> summarizes laboratory abnormalities worsening from baseline to Grade 3 or 4 in ≥1% of patients with dMMR EC on JEMPERLI in GARNET.</paragraph>
                        <table ID="_RefTable_6" width="100%">
                           <caption>Table 6. Laboratory Abnormalities that Worsened from Baseline to Grade 3 or 4 Occurring in ≥1% of Patients with dMMR Endometrial Cancer Receiving JEMPERLI in GARNET</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">dMMR = Mismatch Repair Deficient.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup> Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Laboratory Test</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 150</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Hematology</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Decreased lymphocytes</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>46</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>15</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    Decreased leukocytes</paragraph>
                                    <paragraph>    Decreased neutrophils</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>21</paragraph>
                                    <paragraph>17</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                    <paragraph>2.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Chemistry</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Decreased albumin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>36</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Increased creatinine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>33</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>3.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Increased alkaline phosphatase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>31</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Increased aspartate aminotransferase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>31</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    Increased alanine aminotransferase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>25</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Electrolytes</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Decreased sodium</paragraph>
                                    <paragraph>    Decreased magnesium</paragraph>
                                    <paragraph>    Decreased potassium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>29</paragraph>
                                    <paragraph>28</paragraph>
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>5</paragraph>
                                    <paragraph>2</paragraph>
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>    Increased calcium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Mismatch Repair Deficient Recurrent or Advanced Solid Tumors</content>
                        </paragraph>
                        <paragraph>The safety of JEMPERLI was investigated in 267 patients with recurrent or advanced dMMR solid tumors enrolled in GARNET <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_0a31d7a2-1ce0-485e-b192-8b3dda7b9f77">14.2</linkHtml>)]</content>. Patients received JEMPERLI 500 mg every 3 weeks for 4 cycles followed by 1,000 mg every 6 weeks as an intravenous infusion until disease progression or unacceptable toxicity. Patients with autoimmune disease that required systemic therapy within 2 years of treatment or a medical condition that required immunosuppression were ineligible. The median duration of exposure to JEMPERLI was 25 weeks (range: 1 to 139 weeks).</paragraph>
                        <paragraph>Serious adverse reactions occurred in 34% of patients receiving JEMPERLI. Serious adverse reactions in &gt;2% of patients included abdominal pain (3.7%), sepsis (2.6%), and acute kidney injury (2.2%). Fatal adverse reaction occurred in 1 patient who received JEMPERLI due to respiratory failure.</paragraph>
                        <paragraph>JEMPERLI was permanently discontinued due to adverse reactions in 9% patients; the most common adverse reaction (≥1%) leading to discontinuation was increased alanine aminotransferase (1.1%).</paragraph>
                        <paragraph>Dosage interruptions due to an adverse reaction occurred in 23% of patients who received JEMPERLI. Adverse reactions that required dosage interruption in ≥1% of patients who received JEMPERLI were anemia, pneumonitis, diarrhea, adrenal insufficiency, increased alanine aminotransferase, and increased aspartate aminotransferase.</paragraph>
                        <paragraph>The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, diarrhea, and nausea.</paragraph>
                        <paragraph>
                           <linkHtml href="#_RefTable_7">Table 7</linkHtml> summarizes the adverse reactions that occurred in ≥10% of patients with dMMR recurrent or advanced solid tumors in GARNET.</paragraph>
                        <table ID="_RefTable_7" width="100%">
                           <caption>Table 7. Adverse Reactions (≥10%) in Patients with dMMR Recurrent or Advanced Solid Tumors in GARNET</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">dMMR = Mismatch Repair Deficient.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.<br/>
                                    <sup>a</sup> Includes fatigue and asthenia.<br/>
                                    <sup>b</sup> Includes anemia, decreased hemoglobin, iron deficiency, and iron deficiency anemia.<br/>
                                    <sup>c</sup> Includes rash, rash maculopapular, rash macular, rash erythematous, rash papular, erythema, toxic skin eruption, and pemphigoid.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>d</sup> Includes increased alanine aminotransferase, increased aspartate aminotransferase, increased transaminases, and   hypertransaminasemia.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 267</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>General and administration site</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Fatigue<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>42</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>3.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Pyrexia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Blood and lymphatic system</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Anemia<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>11</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Gastrointestinal</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>25</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>17</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Constipation</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Skin and subcutaneous tissue</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Pruritus</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Rash<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Respiratory, thoracic, and mediastinal</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Cough</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>13</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Metabolism and nutrition</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Decreased appetite</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Investigations</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>     Increased transaminases<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt;10% of patients who received JEMPERLI included:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine Disorders:</content> Hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, autoimmune thyroiditis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders:</content> Uveitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> Colitis, enterocolitis, enterocolitis hemorrhage, pancreatitis, acute pancreatitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions:</content> Chills.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Injury, Poisoning, and Procedural Complications:</content> Infusion related reaction.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary Disorders:</content> Hepatocellular injury.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> Myalgia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders:</content> Nephritis, tubulointerstitial nephritis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders:</content> Pneumonitis, interstitial lung disease.</paragraph>
                        <paragraph>
                           <linkHtml href="#_RefTable_8">Table 8</linkHtml> summarizes laboratory abnormalities worsening from baseline to Grade 3 or 4 in ≥1% of patients with dMMR recurrent or advanced solid tumors in GARNET.</paragraph>
                        <table ID="_RefTable_8" width="100%">
                           <caption>Table 8. Laboratory Abnormalities that Worsened from Baseline to Grade 3 or 4 Occurring in ≥1% of Patients with dMMR Recurrent or Advanced Solid Tumors in GARNET</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">dMMR = Mismatch Repair Deficient.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup> Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Laboratory Test</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 267</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All Grades<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Hematology</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased lymphocytes</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>33</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased leukocytes</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Decreased neutrophils</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Chemistry</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased albumin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>26</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>2.2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased alkaline phosphatase </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>26</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>3.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased aspartate aminotransferase </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>26</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased alanine aminotransferase </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased creatinine </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Increased total bilirubin </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Electrolytes</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased sodium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>4.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased magnesium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Decreased potassium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased potassium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased calcium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>     Increased magnesium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>4.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>     Decreased calcium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>2.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9f21d02c-c2fc-4acc-af21-27fc08e908fa">
               <id root="a7d4e348-e687-46f9-a8bc-11ded42c2b09"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20240801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed. (<linkHtml href="#ID_09a4966a-b637-4504-a23c-7314f971be4d">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_fdc49f15-59dc-428e-9791-85f45526697c">
                     <id root="0e990288-df20-44f0-9f3f-78adb652c1a1"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on its mechanism of action, JEMPERLI can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_2b0842fd-58b6-44dd-a54c-500d6afdbc72">12.1</linkHtml>)]</content>. There are no available data on the use of JEMPERLI in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death <content styleCode="italics">(see )</content>. Human IgG4 immunoglobulins (IgG4) are known to cross the placental barrier; therefore, dostarlimab-gxly has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to a fetus.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data:</content> Animal reproduction studies have not been conducted with JEMPERLI to evaluate its effect on reproduction and fetal development. A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering JEMPERLI during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1/PD-L1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to dostarlimab-gxly may increase the risk of developing immune-mediated disorders or altering the normal immune response.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_09a4966a-b637-4504-a23c-7314f971be4d">
                     <id root="29d5bc65-1929-4535-a255-c4a01a6decc1"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of dostarlimab-gxly in human milk or its effects on the breastfed child or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to JEMPERLI are unknown. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 4 months after the last dose of JEMPERLI.</paragraph>
                     </text>
                     <effectiveTime value="20230209"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_133b43da-b996-4e08-8694-7d62293d02b1">
                     <id root="349559b9-cc2c-448b-a147-736da0b99262"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3	Females and Males of Reproductive Potential </title>
                     <text>
                        <paragraph>JEMPERLI can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_fdc49f15-59dc-428e-9791-85f45526697c">8.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating JEMPERLI <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_fdc49f15-59dc-428e-9791-85f45526697c">8.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females:</content> Advise females of reproductive potential to use effective contraception during treatment with JEMPERLI and for 4 months after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ab602ab7-dc8f-4ae0-b4f8-d0a4ffe5f178">
                     <id root="65268084-36da-48cb-bb9b-c51d555eb2ef"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric Use </title>
                     <text>
                        <paragraph>The safety and efficacy of JEMPERLI have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20200522"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5c5e8d59-532f-445b-b04a-d021b726f295">
                     <id root="d79cde7a-3a9f-430f-a167-39b4586d4eb9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">In Combination with Carboplatin and Paclitaxel</content>
                        </paragraph>
                        <paragraph>Of the 241 patients treated with JEMPERLI in RUBY, 52.3% were younger than 65 years, 36.5% were aged 65 through 74 years, and 11.2% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients.</paragraph>
                        <paragraph>
                           <content styleCode="underline">As a Single Agent</content>
                        </paragraph>
                        <paragraph>Of the 605 patients treated with JEMPERLI in GARNET, 51.6% were younger than 65 years, 36.9% were aged 65 through 74 years, and 11.5% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_152fb665-21cc-43b3-b988-d6ada42079b6">
               <id root="f779a8e1-2bf5-4a81-8c48-bd7832c31c90"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11	DESCRIPTION </title>
               <text>
                  <paragraph>Dostarlimab-gxly is a programmed death receptor-1 (PD-1)–blocking IgG<sub>4</sub> humanized monoclonal antibody. Dostarlimab‑gxly is produced in Chinese hamster ovary cells and has a calculated molecular weight of about 144 kDa.</paragraph>
                  <paragraph>JEMPERLI (dostarlimab-gxly) injection is a sterile, clear to slightly opalescent, colorless to yellow solution essentially free from visible particles. It is supplied as single-dose vials.</paragraph>
                  <paragraph>Each vial contains 500 mg of JEMPERLI in 10 mL of solution with a pH of 6. Each mL of solution contains 50 mg of dostarlimab-gxly, citric acid monohydrate (0.48 mg), L-arginine hydrochloride (21.07 mg), polysorbate 80 (0.2 mg), sodium chloride (1.81 mg), trisodium citrate dihydrate (6.68 mg), and Water for Injection, USP.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="ID_3f4bced0-4098-480f-82f9-d5e42f8b4a81">
               <id root="d3745884-2469-46f3-b2e8-ba8738d4a25c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20240801"/>
               <component>
                  <section ID="ID_2b0842fd-58b6-44dd-a54c-500d6afdbc72">
                     <id root="6f4c4366-7f91-4527-b96c-cfb25dc5e928"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action </title>
                     <text>
                        <paragraph>Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.</paragraph>
                     </text>
                     <effectiveTime value="20200522"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ab87f6b5-2dcf-4a7f-9e37-ad8ce989eb86">
                     <id root="bc80e571-fe68-4c04-affa-90871625db56"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2	Pharmacodynamics </title>
                     <text>
                        <paragraph>The exposure-response relationship and time course of pharmacodynamic response for safety and effectiveness of dostarlimab-gxly have not been fully characterized.</paragraph>
                        <paragraph>Dostarlimab-gxly provides sustained target engagement as measured by direct PD-1 binding and stimulation of IL-2 production throughout the dosing interval at the recommended dosage.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_672d4b46-b941-45ee-a744-043bec1ed55a">
                     <id root="4151cc8a-b1d0-4bbb-ae23-06a2a3247502"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	Pharmacokinetics </title>
                     <text>
                        <paragraph>The pharmacokinetics of dostarlimab-gxly as a single agent and in combination with carboplatin and paclitaxel were evaluated in patients with various solid tumors, including patients with EC. Mean C<sub>max</sub>, AUC<sub>0-inf</sub>, and AUC<sub>0-tau</sub> increased proportionally over the dose range of 1 to 10 mg/kg. The Cycle 1 mean (coefficient of variation [%CV]) C<sub>max</sub> and AUC<sub>0-tau</sub> of dostarlimab-gxly as a single agent were 171 mcg/mL (20%) and 35,730 mcg*h/mL (20%), respectively at the dosage of 500 mg once every 3 weeks and 309 mcg/mL (31%) and 95,820 mcg*h/mL (29%), respectively at the dosage of 1,000 mg every 6 weeks.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The mean (%CV) volume of distribution of dostarlimab-gxly at steady state is approximately 5.8 L (15%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The mean terminal elimination half-life of dostarlimab-gxly at steady state is 23.5 days and its mean (%CV) clearance at steady state is 0.007 L/h (30%).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism:</content> Dostarlimab-gxly is expected to be metabolized into small peptides and amino acids by catabolic pathways.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of dostarlimab-gxly were observed based on age (24 to 86 years), sex, race/ethnicity (75% White, 2% Asian, and 5% African American), tumor type, and renal impairment based on the estimated creatinine clearance (eGFR ≥15 mL/min/1.73 m<sup>2</sup>), and mild to moderate hepatic impairment [total bilirubin (TB) &gt;ULN to 3 times ULN or AST&gt;ULN to any AST].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>Dostarlimab exposure when administered in combination with carboplatin and paclitaxel was comparable to single agent exposure and there was no evidence to suggest a clinically relevant change of dostarlimab-gxly clearance over time in patients with recurrent or advanced EC.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_82dfe81a-8823-472c-8e1f-5b13b4b75643">
                     <id root="c80783e6-3f85-4551-800e-5d2b08629a7b"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6	Immunogenicity </title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of JEMPERLI or of other dostarlimab-gxly products.</paragraph>
                        <paragraph>The immunogenicity of dostarlimab-gxly was evaluated in RUBY at a dosage of 500 mg every 3 weeks for 6 cycles followed by 1,000 mg every 6 weeks thereafter; there was no formation of anti-drug antibodies and neutralizing antibodies in 225 patients receiving JEMPERLI at the recommended dosage.</paragraph>
                        <paragraph>The immunogenicity of dostarlimab-gxly was evaluated in GARNET at a dose of 500 mg every 3 weeks for 4 cycles followed by 1,000 mg every 6 weeks thereafter. Anti‑drug antibodies against dostarlimab-gxly were detected in 2.1% (8/384) of patients who received JEMPERLI at the recommended dosage. Neutralizing antibodies were detected in 1% (4/384) of patients.</paragraph>
                        <paragraph>Because of the small number of patients who developed anti-drug antibodies, the effect of immunogenicity on the pharmacokinetics, efficacy, and safety of dostarlimab-gxly is inconclusive.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f1b2eaaf-45bf-4efc-bb3e-43bfbdcfb063">
               <id root="937d1eac-281e-4e8e-8bcd-c0fc543e55a1"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20230209"/>
               <component>
                  <section ID="ID_fc3a08ef-d503-4991-bab8-761142cbd3cf">
                     <id root="0dedea22-37e9-450d-9616-d56dba8230f1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>No studies have been performed to assess the potential of dostarlimab-gxly for carcinogenicity or genotoxicity.</paragraph>
                        <paragraph>Fertility studies have not been conducted with dostarlimab-gxly. In 1- and 3-month repeat‑dose toxicology studies in monkeys, there were no notable effects in the male and female reproductive organs; however, many animals in these studies were not sexually mature.</paragraph>
                     </text>
                     <effectiveTime value="20200522"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1e9ce1bd-d968-4540-8b89-dde78dcb0b08">
                     <id root="e735e04b-efed-454c-8b67-6b27431c8f75"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2	Animal Toxicology and/or Pharmacology </title>
                     <text>
                        <paragraph>In animal models, inhibition of PD-L1/PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. <content styleCode="italics">Mycobacterium tuberculosis</content>-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-1 blockade using a primate anti-PD-1 antibody was also shown to exacerbate <content styleCode="italics">M. tuberculosis </content>infection in rhesus macaques. PD-L1 and PD-1 knockout mice and mice receiving PD-L1–blocking antibody have also shown decreased survival following infection with lymphocytic choriomeningitis virus.</paragraph>
                     </text>
                     <effectiveTime value="20230209"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7974db8e-a8bc-4d24-b64b-3723e894938f">
               <id root="50941baa-f32f-45c9-a8bf-871b53bb5dc2"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES </title>
               <effectiveTime value="20240801"/>
               <component>
                  <section ID="ID_cca2cd2a-8ab4-4352-a019-13d0b81835ed">
                     <id root="ed406674-beac-41c4-a0a6-8704bcbacea1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Endometrial Cancer </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">In Combination with Carboplatin and Paclitaxel for the Treatment of Primary Advanced or Recurrent Endometrial Cancer</content>
                        </paragraph>
                        <paragraph>The efficacy of JEMPERLI in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, was evaluated in RUBY (NCT03981796), a randomized, multicenter, double-blind, placebo-controlled trial conducted in 494 patients with primary advanced or recurrent EC.</paragraph>
                        <paragraph>The trial enrolled patients with primary Stage III or Stage IV disease (per FIGO Staging Classification), including Stage IIIA to IIIC1 patients with evaluable or measurable disease, Stage IIIC1 patients with carcinosarcoma, clear cell, serous, or mixed histology regardless of presence of evaluable or measurable disease, Stage IIIC2 or Stage IV disease regardless of presence of evaluable or measurable disease. The trial also enrolled patients with first recurrent disease with a low potential for cure by radiation therapy or surgery alone or in combination, including patients who were naïve to systemic anticancer therapy or who had received prior neo-adjuvant/adjuvant systemic anticancer therapy and had a recurrence or disease progression ≥6 months after completing treatment.</paragraph>
                        <paragraph>Patients were randomized (1:1) to one of the following treatments arms:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>JEMPERLI 500 mg, carboplatin AUC 5 mg/mL/min, paclitaxel 175 mg/m<sup>2</sup> intravenously on Day 1 of each 21-day cycle for 6 cycles followed by JEMPERLI 1,000 mg intravenously every 6 weeks. JEMPERLI was administered prior to chemotherapy on Day 1.</item>
                           <item>
                              <caption>•</caption>Placebo, carboplatin AUC 5 mg/mL/min, paclitaxel 175 mg/m<sup>2</sup> intravenously on Day 1 of each 21-day cycle for 6 cycles followed by placebo intravenously every 6 weeks.</item>
                        </list>
                        <paragraph>Randomization was stratified by mismatch repair (MMR)/microsatellite instability (MSI) status, prior external pelvic radiotherapy, and disease status (recurrent, primary Stage III, or primary Stage IV). Treatment with JEMPERLI continued until disease progression, unacceptable toxicity, or a maximum of 3 years. Administration of JEMPERLI was permitted beyond disease progression (defined by Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) if the patient was clinically stable and considered to be deriving clinical benefit by the investigator.</paragraph>
                        <paragraph>Assessment of tumor status was performed every 6 weeks through Week 25, every 9 weeks through Week 52 and every 12 weeks thereafter. The major efficacy outcomes were Progression-Free Survival (PFS) using RECIST v1.1 as assessed by investigator in the dMMR/MSI-H and overall populations, and Overall Survival (OS) in the overall population. Additional efficacy outcome measures included Objective Response Rate (ORR) per RECIST v1.1 as assessed by investigator and Duration of Response (DOR).</paragraph>
                        <paragraph>Among the 494 patients evaluated, the baseline characteristics were: median age 65 years (51% aged 65 years or older); 77% White, 12% Black, 3% Asian, 3% Hispanic or Latino; Eastern Cooperative Oncology Group (ECOG) Performance Status 0 (63%) or 1 (37%); and primary stage III (18%); primary stage IV (34%) and recurrent EC (48%). Overall, 24% were dMMR/MSI-H tumors and 76% were mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumors.</paragraph>
                        <paragraph>Efficacy results are presented in <linkHtml href="#_RefTable_9">Table 9</linkHtml> and Figures ,  and . Treatment with JEMPERLI in combination with carboplatin and paclitaxel demonstrated statistically significant improvements in OS in the overall population and PFS in both the dMMR/MSI-H and overall population versus placebo in combination with carboplatin and paclitaxel. Pre-specified exploratory analyses of PFS and OS were performed in patients with MMRp/MSS EC.</paragraph>
                        <table ID="_RefTable_9" width="100%">
                           <caption>Table 9. Efficacy Results of Endometrial Cancer Population in RUBY</caption>
                           <col width="28%"/>
                           <col width="19%"/>
                           <col width="15%"/>
                           <col width="18%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">dMMR = Mismatch Repair Deficient; MSI-H = Microsatellite Instability-High; NR = Not Reached; + = ongoing at last assessment.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Based on stratified Cox regression model.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>b</sup> One-sided P-value based on stratified log-rank test.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>c</sup> Confirmed responses.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Endpoint</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Overall Population</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">dMMR/MSI-H Population</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI with Carboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 245</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo with Carboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 249</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI with Carboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 60</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo withCarboplatin and Paclitaxel</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 62</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Overall Survival (OS)</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="bottom"/>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Number (%) of patients with event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>109 (44)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>144 (58)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>15 (25)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>35 (56)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>     Median in months</paragraph>
                                    <paragraph>      (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>44.6</paragraph>
                                    <paragraph>(32.6, NR)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>28.2</paragraph>
                                    <paragraph>(22.1, 35.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>NR</paragraph>
                                    <paragraph>(NR, NR)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>30.8</paragraph>
                                    <paragraph>(18.7, NR)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Hazard ratio (95% CI)<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.69 (0.54, 0.89)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.34 (0.18, 0.62)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>     <content styleCode="italics">P</content>-value<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.002</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Not tested</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Progression-Free Survival (PFS)</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Number (%) of patients with event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>135 (55)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>177 (71)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>23 (38)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>47 (76)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Median in months </paragraph>
                                    <paragraph>      (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>11.8</paragraph>
                                    <paragraph>(9.6, 17.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>7.9</paragraph>
                                    <paragraph>(7.6, 9.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>30.3</paragraph>
                                    <paragraph>(11.8, NR)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>7.7</paragraph>
                                    <paragraph>(5.6, 9.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Hazard ratio (95% CI)<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.64 (0.51, 0.80)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.29 (0.17, 0.50)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     <content styleCode="italics">P-</content>value<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>&lt;0.0001</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>&lt;0.0001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Objective Response Rate (ORR)</content>
                                       <sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Number of participants with measurable disease at baseline (n)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>172</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>185</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>42</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>45</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     ORR (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>68%</paragraph>
                                    <paragraph>(60, 75)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>57%</paragraph>
                                    <paragraph>(50, 65)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>74%</paragraph>
                                    <paragraph>(58, 86)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>62%</paragraph>
                                    <paragraph>(47, 76)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Complete response rate</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>20%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>12%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>26%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>11%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Partial response rate</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>48%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>45%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>48%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>51%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Duration of Response (DOR)</content>
                                       <sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>     Median in months (range)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>10.8</paragraph>
                                    <paragraph>(1.3+, 28.9+)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>6.4</paragraph>
                                    <paragraph>(1.4+, 27.2+)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>NR</paragraph>
                                    <paragraph>(3.4, 28.3+)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>5.4</paragraph>
                                    <paragraph>(2.7, 27.2+)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In patients with MMRp/MSS EC (n = 372), the OS hazard ratio (HR) was 0.82 (95% CI: 0.62, 1.08) with a median OS of 32.5 (95% CI: 28.6, NR) months for JEMPERLI in combination with carboplatin and paclitaxel versus 28.2 (95% CI: 21.9, 36.1) months for placebo in combination with carboplatin and paclitaxel. The PFS HR was 0.78 (95% CI: 0.60, 1.00) with a median PFS of 9.8 (95% CI: 9.0, 12.6) months for JEMPERLI in combination with carboplatin and paclitaxel (n = 185) versus 7.9 (95% CI: 7.6, 9.8) months for placebo in combination with carboplatin and paclitaxel (n = 187).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1. Kaplan-Meier Curve for Overall Survival in Patients (Overall Population) with Endometrial Cancer in RUBY</content>
                        </paragraph>
                        <renderMultiMedia ID="id-1544054062" referencedObject="ID_561ba10a-5a27-48d6-a724-befc8b077337"/>
                        <paragraph>
                           <content styleCode="bold">Figure 2. Kaplan-Meier Curve for Progression-Free Survival in Patients (Overall Population) with Endometrial Cancer in RUBY</content>
                        </paragraph>
                        <renderMultiMedia ID="id648954060" referencedObject="A2385BEB-AC66-4F68-B2D0-A9475BB0F300"/>
                        <paragraph>
                           <content styleCode="bold">Figure 3. Kaplan-Meier Curve for Progression-Free Survival in Patients with dMMR/MSI-H Endometrial Cancer in RUBY</content>
                        </paragraph>
                        <renderMultiMedia ID="id435488666" referencedObject="ID_0bc8ac1f-581f-4e0d-98b6-8cf90833b6d0"/>
                        <paragraph>dMMR = Mismatch Repair Deficient; MSI-H = Microsatellite Instability High.</paragraph>
                        <paragraph>
                           <content styleCode="underline">As a Single Agent for the Treatment of dMMR Recurrent or Advanced Endometrial Cancer</content>
                        </paragraph>
                        <paragraph>The efficacy of JEMPERLI as a single agent was evaluated in the GARNET trial (NCT02715284), a multicenter, multicohort, open-label trial conducted in patients with advanced solid tumors. The efficacy population consisted of a cohort of 141 patients with dMMR recurrent or advanced EC who had progressed on or after treatment with a platinum‑containing regimen. Patients with prior treatment with PD‑1/PD‑L1–blocking antibodies or other immune checkpoint inhibitor therapy and patients with autoimmune disease that required systemic therapy with immunosuppressant agents within 2 years were excluded from the trial.</paragraph>
                        <paragraph>Patients received JEMPERLI 500 mg intravenously every 3 weeks for 4 doses followed by 1,000 mg intravenously every 6 weeks. Treatment continued until disease progression or unacceptable toxicity. The major efficacy outcome measures were ORR and DOR as assessed by blinded independent central review (BICR) according to the RECIST v 1.1.</paragraph>
                        <paragraph>The baseline characteristics were: median age 65 years (53% aged 65 years or older); 77% White, 4% Asian, 3% Black, 4% Hispanic or Latino; and Eastern Cooperative Oncology Group Performance Status 0 (38%) or 1 (62%).</paragraph>
                        <paragraph>The most common histology seen was endometrioid carcinoma type 1 (65%), Grade 3 endometrioid (15%), followed by serous (5%), mixed (5%) and undifferentiated (2.8%).</paragraph>
                        <paragraph>All patients with dMMR EC had received prior anticancer treatment, with 89% of patients receiving prior anticancer surgery and 71% receiving prior anticancer radiotherapy. Sixty-three percent of patients had one prior line of anticancer treatment and 37% had two or more prior lines. Forty-eight patients (34%) received treatment only in the neoadjuvant or adjuvant setting before participating in the study.</paragraph>
                        <paragraph>The dMMR tumor status was retrospectively confirmed using the VENTANA MMR RxDx Panel assay.</paragraph>
                        <paragraph>Efficacy results are presented in <linkHtml href="#_RefTable_10">Table 10</linkHtml>.</paragraph>
                        <table ID="_RefTable_10" width="100%">
                           <caption>Table 9. Efficacy Results of dMMR Endometrial Cancer Population in GARNET</caption>
                           <col width="53%"/>
                           <col width="47%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2" valign="top">dMMR = Mismatch Repair Deficient; + = ongoing at last assessment.<br/>
                                    <sup>a</sup> Based on confirmed response by blinded independent central review.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="2" valign="top">
                                    <sup>b</sup> Median follow up for duration of response was 27.9 months measured from time of first response.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Endpoint</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N</content> <content styleCode="bold">= 141</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Overall response rate<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    ORR (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>45.4% (37.0, 54.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Complete response rate</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>15.6%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    Partial response rate</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>29.8%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Duration of response<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Median in months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Not reached</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    (range)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>(1.2+, 52.8+)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Patients with duration ≥12 months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>85.9%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>    Patients with duration &gt;24 months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>54.7%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240801"/>
                     <component>
                        <observationMedia ID="ID_561ba10a-5a27-48d6-a724-befc8b077337">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="jemperli-spl-graphic-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="A2385BEB-AC66-4F68-B2D0-A9475BB0F300">
                           <text>Figure 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="jemperli-spl-graphic-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_0bc8ac1f-581f-4e0d-98b6-8cf90833b6d0">
                           <text>Figure 3</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="jemperli-spl-graphic-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_0a31d7a2-1ce0-485e-b192-8b3dda7b9f77">
                     <id root="90890ca9-d743-44b4-8262-db4dd8a35ec8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Mismatch Repair Deficient Recurrent or Advanced Solid Tumors </title>
                     <text>
                        <paragraph>The efficacy of JEMPERLI as a single agent was evaluated in GARNET (NCT02715284), a non‑randomized, multicenter, open-label, multicohort trial. The efficacy population consisted of a cohort of 209 patients with dMMR recurrent or advanced solid tumors who progressed following systemic therapy and had no satisfactory alternative treatment options. Patients with dMMR EC must have progressed on or after treatment with a platinum-containing regimen. Patients with dMMR colorectal cancer must have progressed after or been intolerant to a fluoropyrimidine, oxaliplatin, and irinotecan.</paragraph>
                        <paragraph>Patients with prior treatment with PD‑1/PD‑L1–blocking antibodies or other immune checkpoint inhibitor therapy and patients with autoimmune disease that required systemic therapy with immunosuppressant agents within 2 years were excluded from the trial.</paragraph>
                        <paragraph>Patients received JEMPERLI 500 mg intravenously every 3 weeks for 4 doses followed by 1,000 mg intravenously every 6 weeks. Treatment continued until disease progression or unacceptable toxicity. </paragraph>
                        <paragraph>The major efficacy outcome measures were ORR and DOR as determined by a BICR according to RECIST v 1.1.</paragraph>
                        <paragraph>The baseline characteristics were female (77%); median age 63 years (47% aged 65 years or older); 63% White, 3% Asian, 2% Black; and Eastern Cooperative Oncology Group Performance Status 0 (39%) or 1 (61%). </paragraph>
                        <paragraph>At time of trial entry, 97.2% of patients (103/106) with non-endometrial dMMR solid tumors had Stage IV disease, and 68.0% (70/103) of patients with dMMR endometrial tumors had FIGO Stage IV disease.</paragraph>
                        <paragraph>Approximately 43% of patients had received 1 prior line of systemic anticancer treatment, 36% had received 2 prior lines, and 21% had received 3 or more prior lines.</paragraph>
                        <paragraph>The dMMR tumor status was retrospectively confirmed using the VENTANA MMR RxDx Panel assay.</paragraph>
                        <paragraph>Efficacy results are presented in Tables <linkHtml href="#_RefTable_11">11</linkHtml> and <linkHtml href="#_RefTable_12">12</linkHtml>.</paragraph>
                        <table ID="_RefTable_11" width="100%">
                           <caption>Table 10. Efficacy Results of dMMR Recurrent or Advanced Solid Tumors in GARNET</caption>
                           <col width="51%"/>
                           <col width="49%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2" valign="top">dMMR = Mismatch Repair Deficient; + = ongoing at last assessment.<br/>
                                    <sup>a</sup> Based on confirmed response by blinded independent central review.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="2" valign="top">
                                    <sup>b</sup> Median follow-up for duration of response was 17.5 months measured from time of first response.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Endpoint</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JEMPERLI</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N</content> <content styleCode="bold">= 209</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Overall response rate<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    ORR (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>41.6% (34.9, 48.6)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Complete response rate</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>9.1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    Partial response rate</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>32.5%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Duration of response<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Median in months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>34.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    (range)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>2.6, 35.8+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>    Patients with duration ≥6 months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>95.4%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_RefTable_12" width="100%">
                           <caption>Table 11. Efficacy Results of dMMR Tumor Types in GARNET</caption>
                           <col width="24%"/>
                           <col width="15%"/>
                           <col width="24%"/>
                           <col width="15%"/>
                           <col width="24%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">CR = complete response; CRC = colorectal cancer; dMMR = Mismatch Repair Deficient; DOR = Duration of Response; EC = endometrial cancer; ORR = Overall Response Rate; PD = progressive disease; PR = partial response; SD = stable disease; + = ongoing at last assessment.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Exact, 2-sided 95% CI for binomial proportion.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Tumor Type</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Patients</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">ORR</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(per RECIST v 1.1)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">DOR</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">95% CI<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Range (months)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>EC</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>103</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>46 (44.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>(34.9, 54.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>2.6, 35.8+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>non-EC</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>106</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>41 (38.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>(29.4, 48.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>5.6, 30.1+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    CRC</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>69</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>25 (36.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>(25.0, 48.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>5.6, 30.1+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Small intestinal cancer</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>4 (33.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>(9.9, 65.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>11.1+, 28.0+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Gastric cancers</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>3 (37.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>(8.5, 75.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>8.4+, 17.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Pancreatic carcinoma</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>(0.0, 60.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Biliary neoplasm</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>CR, CR</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>8.4+, 13.5+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Liver cancer</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>PR, PD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>13.8+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Ovarian cancer</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>PR, SD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>25.1+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Adrenal cortical</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>PR</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>19.5+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Breast cancer</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>CR</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>16.8+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Esophageal cancer</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>PD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Genital neoplasm malignant female</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>PR</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>22.2+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Pleural</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>PR</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>15.2+</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Renal cell carcinoma</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule " valign="bottom">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>SD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>    Unknown origin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>PR</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>20.4+</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_10729313-d18d-42f3-b7ab-b1a9859c24a4">
               <id root="98d81174-0aea-4e7c-8aac-48e4c29b589a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>JEMPERLI (dostarlimab-gxly) injection is a clear to slightly opalescent, colorless to yellow solution supplied in a carton containing one 500 mg/10 mL (50 mg/mL), single-dose vial (NDC 0173-0898-03).</paragraph>
                  <paragraph>Store vial refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze or shake.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="ID_0d6f7504-4477-442d-9750-228767de0934">
               <id root="79cd1de3-9002-4cfd-b24a-857ff3576213"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17	PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Immune-Mediated Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk of immune-mediated adverse reactions that may be severe or fatal, may occur after discontinuation of treatment, and may require corticosteroid or other treatment and interruption or discontinuation of JEMPERLI. These reactions may include:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Pneumonitis: Advise patients to contact their healthcare provider immediately for new or worsening cough, chest pain, or shortness of breath <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Colitis: Advise patients to contact their healthcare provider immediately for diarrhea or severe abdominal pain <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, or easy bruising or bleeding <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Immune-mediated endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypothyroidism, hyperthyroidism, thyroiditis, adrenal insufficiency, hypophysitis, or type 1 diabetes mellitus <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Nephritis: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Severe skin reactions: Advise patients to contact their healthcare provider immediately for any signs or symptoms of severe skin reactions, SJS, TEN, or DRESS <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Other immune-mediated adverse reactions:<list listType="unordered">
                           <item>
                              <caption>o</caption>Advise patients that immune-mediated adverse reactions can occur and may involve any organ system, and to contact their healthcare provider immediately for any new signs or symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                           <item>
                              <caption>o</caption>Advise patients of the risk of solid organ transplant rejection and to contact their healthcare provider immediately for signs or symptoms of organ transplant rejection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4984c2ce-7d02-4519-ad57-91e478a379a5">5.1</linkHtml>)]</content>.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Infusion-Related Reactions</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_b6dd660a-5c83-4779-80cb-1008df33d0ab">5.2</linkHtml>)].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Complications of Allogeneic HSCT </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Advise patients of the risk of post-allogeneic hematopoietic stem cell transplantation complications <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_77ae6955-4971-43bc-a718-a357905f28c5">5.3</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_982b8f4b-e023-43b1-ba00-d7a7ef9c5079">5.4</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_fdc49f15-59dc-428e-9791-85f45526697c">8.1</linkHtml>, <linkHtml href="#ID_133b43da-b996-4e08-8694-7d62293d02b1">8.3</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Advise females of reproductive potential to use effective contraception during treatment with JEMPERLI and for 4 months after the last dose <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_982b8f4b-e023-43b1-ba00-d7a7ef9c5079">5.4</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_fdc49f15-59dc-428e-9791-85f45526697c">8.1</linkHtml>, <linkHtml href="#ID_133b43da-b996-4e08-8694-7d62293d02b1">8.3</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Advise women not to breastfeed during treatment with JEMPERLI and for 4 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_09a4966a-b637-4504-a23c-7314f971be4d">8.2</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>GlaxoSmithKline LLC</paragraph>
                  <paragraph>Philadelphia, PA 19104</paragraph>
                  <paragraph>U.S. License No. 1727</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>GlaxoSmithKline</paragraph>
                  <paragraph>Durham, NC 27701</paragraph>
                  <paragraph>©2024 GSK group of companies or its licensor.</paragraph>
                  <paragraph>JMP:7PI</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="ID_35796f05-da0c-4373-aa65-6dc9dc01a258">
               <id root="2c80a1e9-0cb0-4815-aab3-4d748dd207aa"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="33%"/>
                     <col width="34%"/>
                     <col width="34%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">JEMPERLI (jem-PER-lee)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(dostarlimab-gxly)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">injection</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about JEMPERLI?</content>
                              </paragraph>
                              <paragraph>JEMPERLI is a medicine that may treat certain cancers by working with your immune system. JEMPERLI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Lung problems.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>cough</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>chest pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Intestinal problems.</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>diarrhea or more bowel movements than usual</item>
                                 <item>
                                    <caption>•</caption>stools that are black, tarry, sticky, or have blood or mucus</item>
                                 <item>
                                    <caption>•</caption>severe stomach-area (abdomen) pain or tenderness</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Liver problems.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>yellowing of your skin or the whites of your eyes</item>
                                 <item>
                                    <caption>•</caption>severe nausea or vomiting</item>
                                 <item>
                                    <caption>•</caption>pain on the right side of your stomach-area (abdomen)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>dark urine (tea colored)</item>
                                 <item>
                                    <caption>•</caption>bleeding or bruising more easily than usual</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Hormone gland problems.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>headaches that will not go away or unusual headaches</item>
                                 <item>
                                    <caption>•</caption>eye sensitivity to light</item>
                                 <item>
                                    <caption>•</caption>eye problems </item>
                                 <item>
                                    <caption>•</caption>rapid heartbeat</item>
                                 <item>
                                    <caption>•</caption>increased sweating</item>
                                 <item>
                                    <caption>•</caption>extreme tiredness</item>
                                 <item>
                                    <caption>•</caption>weight gain or weight loss</item>
                                 <item>
                                    <caption>•</caption>feeling more hungry or thirsty than usual</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>urinating more often than usual</item>
                                 <item>
                                    <caption>•</caption>hair loss</item>
                                 <item>
                                    <caption>•</caption>feeling cold</item>
                                 <item>
                                    <caption>•</caption>constipation</item>
                                 <item>
                                    <caption>•</caption>your voice gets deeper</item>
                                 <item>
                                    <caption>•</caption>dizziness or fainting</item>
                                 <item>
                                    <caption>•</caption>changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Kidney problems.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>change in the amount or color of your urine</item>
                                 <item>
                                    <caption>•</caption>blood in your urine</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>swelling in your ankles</item>
                                 <item>
                                    <caption>•</caption>loss of appetite</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Skin problems.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>rash</item>
                                 <item>
                                    <caption>•</caption>itching</item>
                                 <item>
                                    <caption>•</caption>skin blistering or peeling</item>
                                 <item>
                                    <caption>•</caption>swollen lymph nodes</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>painful sores or ulcers in your mouth or in your nose, throat, or genital area</item>
                                 <item>
                                    <caption>•</caption>fever or flu-like symptoms</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with JEMPERLI. Call or see your healthcare provider right away for any new or worse signs or symptoms.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>chest pain, irregular heartbeat, shortness of breath, swelling of ankles</item>
                                 <item>
                                    <caption>•</caption>confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs</item>
                                 <item>
                                    <caption>•</caption>double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight</item>
                                 <item>
                                    <caption>•</caption>persistent or severe muscle pain or weakness, muscle cramps</item>
                                 <item>
                                    <caption>•</caption>low red blood cells, bruising</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Infusion reactions that can sometimes be severe or life-threatening. </content>Signs and symptoms of infusion reactions may include:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>chills or shaking</item>
                                 <item>
                                    <caption>•</caption>itching or rash</item>
                                 <item>
                                    <caption>•</caption>flushing</item>
                                 <item>
                                    <caption>•</caption>shortness of breath or wheezing</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>dizziness</item>
                                 <item>
                                    <caption>•</caption>feel like passing out</item>
                                 <item>
                                    <caption>•</caption>fever</item>
                                 <item>
                                    <caption>•</caption>back or neck pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Rejection of a transplanted organ. </content>Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). </content>These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with JEMPERLI. Your healthcare provider will monitor you for these complications.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Getting medical treatment right away may help keep these problems from becoming more serious.</content>
                              </paragraph>
                              <paragraph>Your healthcare provider will check you for these problems during treatment with JEMPERLI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with JEMPERLI, if you have severe side effects.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is JEMPERLI?</content>
                              </paragraph>
                              <paragraph>JEMPERLI is a prescription medicine used to treat adults with:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>a kind of uterine cancer called endometrial cancer (EC)<list listType="unordered">
                                       <item>
                                          <caption>o</caption>JEMPERLI may be used in combination with the chemotherapy medicines carboplatin and paclitaxel, and then after that, JEMPERLI may be used alone:<list listType="unordered">
                                             <item>
                                                <caption>▪</caption>when your cancer has spread outside your uterus (advanced) <content styleCode="bold">or</content>,</item>
                                             <item>
                                                <caption>▪</caption>your cancer has returned.</item>
                                          </list>
                                       </item>
                                       <item>
                                          <caption>o</caption>JEMPERLI may be used alone:<list listType="unordered">
                                             <item>
                                                <caption>▪</caption>when a laboratory test shows that your tumor is mismatch repair deficient (dMMR), <content styleCode="bold">and</content>
                                             </item>
                                             <item>
                                                <caption>▪</caption>your cancer has returned, or it has spread (advanced EC), <content styleCode="bold">and</content>
                                             </item>
                                             <item>
                                                <caption>▪</caption>you have received chemotherapy that contains platinum, and it did not work or is no longer working, <content styleCode="bold">and</content>
                                             </item>
                                             <item>
                                                <caption>▪</caption>your cancer cannot be treated by surgery or radiation.</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>a kind of cancer that is shown by laboratory test to be mismatch repair deficient (dMMR) solid tumor. JEMPERLI may be used alone to treat:<list listType="unordered">
                                       <item>
                                          <caption>o</caption>cancer that has returned or has spread (advanced cancer) <content styleCode="bold">and</content>,</item>
                                       <item>
                                          <caption>o</caption>has progressed during treatment or after treatment, and you have no satisfactory treatment options.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>It is not known if JEMPERLI is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before receiving JEMPERLI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have immune system problems, such as Crohn’s disease, ulcerative colitis, or lupus.</item>
                                 <item>
                                    <caption>•</caption>have received an organ transplant.</item>
                                 <item>
                                    <caption>•</caption>have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic).</item>
                                 <item>
                                    <caption>•</caption>have received radiation treatment to your chest area.</item>
                                 <item>
                                    <caption>•</caption>have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome.</item>
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. JEMPERLI can harm your unborn baby.</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Females who are able to become pregnant:</content>
                                    <list listType="ordered">
                                       <item>
                                          <caption>1.</caption>Your healthcare provider will do a pregnancy test before you start treatment with JEMPERLI.</item>
                                       <item>
                                          <caption>2.</caption>You should use an effective method of birth control during your treatment and for 4 months after your last dose of JEMPERLI. Talk to your healthcare provider about birth control methods that you can use during this time.</item>
                                       <item>
                                          <caption>3.</caption>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JEMPERLI.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if JEMPERLI passes into your breast milk. Do not breastfeed during treatment and for 4 months after your last dose of JEMPERLI.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How will I receive JEMPERLI?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Your healthcare provider will give you JEMPERLI into your vein through an intravenous (IV) line over 30 minutes.</item>
                                 <item>
                                    <caption>•</caption>When JEMPERLI is used in combination with carboplatin and paclitaxel, JEMPERLI is usually given every 3 weeks for the first 6 doses. Beginning 3 weeks later, it is usually given alone every 6 weeks.</item>
                                 <item>
                                    <caption>•</caption>When JEMPERLI is used alone to treat dMMR recurrent or advanced EC and dMMR recurrent or advanced solid tumors, it is usually given every 3 weeks for the first 4 doses. Beginning 3 weeks later, it is usually given every 6 weeks.</item>
                                 <item>
                                    <caption>•</caption>Your healthcare provider will decide how many treatments you need.</item>
                                 <item>
                                    <caption>•</caption>Your healthcare provider will do blood tests to check you for side effects.</item>
                                 <item>
                                    <caption>•</caption>If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of JEMPERLI?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">JEMPERLI can cause serious side effects. </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">See “What is the most important information I should know about JEMPERLI?”</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of JEMPERLI when given with carboplatin and paclitaxel in people with EC include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>nerve problems in your arms, hands, legs, and feet</item>
                                 <item>
                                    <caption>•</caption>tiredness</item>
                                 <item>
                                    <caption>•</caption>nausea</item>
                                 <item>
                                    <caption>•</caption>hair loss</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>joint pain</item>
                                 <item>
                                    <caption>•</caption>rash</item>
                                 <item>
                                    <caption>•</caption>constipation</item>
                                 <item>
                                    <caption>•</caption>diarrhea</item>
                                 <item>
                                    <caption>•</caption>stomach-area (abdomen) pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>shortness of breath</item>
                                 <item>
                                    <caption>•</caption>decreased appetite</item>
                                 <item>
                                    <caption>•</caption>urinary tract infections</item>
                                 <item>
                                    <caption>•</caption>vomiting</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of JEMPERLI in people with dMMR solid tumors (including EC) when used alone include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>tiredness and weakness</item>
                                 <item>
                                    <caption>•</caption>low red blood cell count (anemia)</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>diarrhea</item>
                                 <item>
                                    <caption>•</caption>nausea</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>constipation</item>
                                 <item>
                                    <caption>•</caption>vomiting</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>These are not all of the possible side effects of JEMPERLI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of JEMPERLI.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you would like more information about JEMPERLI, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about JEMPERLI that is written for healthcare professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in JEMPERLI?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> dostarlimab-gxly</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients</content>: citric acid monohydrate, L-arginine hydrochloride, polysorbate 80, sodium chloride, trisodium citrate dihydrate, and Water for Injection.</paragraph>
                              <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                              <paragraph>Manufactured by:</paragraph>
                              <paragraph>GlaxoSmithKline LLC, Philadelphia, PA 19104, U.S. License No. 1727</paragraph>
                              <paragraph>Distributed by:</paragraph>
                              <paragraph>GlaxoSmithKline, Durham, NC 27701 </paragraph>
                              <paragraph>©2024 GSK group of companies or its licensor.</paragraph>
                              <paragraph>JMP:5MG</paragraph>
                              <paragraph>For more information, call 1-888-825-5249 or go to www.gsk.com.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.                Revised: August 2024</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="ID_4f11a7f5-4b11-4c3b-85c4-d8f17a1ff080">
               <id root="4c519117-68a7-40dc-b672-29805f3e6f1f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0173-0898-03</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Jemperli</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(dostarlimab-gxly) Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg/10 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(50 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">gsk</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Infusion after Dilution</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Single-Dose Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the enclosed Medication Guide to each patient</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">©2020 GSK group of companies or its licensor.</content>
                  </paragraph>
                  <paragraph>Rev. 3/23</paragraph>
                  <paragraph>PCR-0022923</paragraph>
                  <renderMultiMedia ID="id1539010501" referencedObject="ID_547c84cd-20bf-4173-a3cc-0f3dcc680bbb"/>
               </text>
               <effectiveTime value="20240801"/>
               <component>
                  <observationMedia ID="ID_547c84cd-20bf-4173-a3cc-0f3dcc680bbb">
                     <text>Jemperli 10 mL carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="jemperli-spl-graphic-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>